{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.1","upperLimit":"9.2","value":"6.8"},{"groupId":"OG001","lowerLimit":"6.3","upperLimit":"10.6","value":"7.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"description":"Overall survival (OS) is defined as the time from the first dose of study medication until death due to any cause. OS was censored using the date of last known contact for those participants who were alive at the time of analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who received no prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.","id":"OG000","title":"GSK2118436 150 mg: No Prior Local Therapy"},{"description":"Participants who received prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.","id":"OG001","title":"GSK2118436 150 mg: Prior Local Therapy"}],"paramType":"MEDIAN","populationDescription":"V600E Population","reportingStatus":"POSTED","timeFrame":"Time from the first dose of study medication until death due to any cause (average of 35 weeks)","title":"Overall Survival of V600E Mutation-positive Participants","type":"SECONDARY","unitOfMeasure":"months"}